Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Reviews |18 March 2003

Evaluation of 21st-Century Risks of Smallpox Vaccination and Policy Options Free

J. Michael Lane, MD, MPH; Joel Goldstein, MD

J. Michael Lane, MD, MPH
From Atlanta, Georgia, and Morrow, Georgia.

Joel Goldstein, MD
From Atlanta, Georgia, and Morrow, Georgia.

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
  • From Atlanta, Georgia, and Morrow, Georgia.

    Potential Financial Conflicts of Interest:Consultancies: J.M. Lane (Centers for Disease Control and Prevention, National Institutes of Health, Walter Reed Army Institute of Research, Acambis, and Dynport).

    Requests for Single Reprints: J. Michael Lane, MD, MPH, 869 Clifton Road NE, Atlanta, GA 30307-1223.

    Current Author Addresses: Dr. Lane: 869 Clifton Road NE, Atlanta, GA 30307-1223.

    Dr. Goldstein: The Children's Clinic, 1000 Corporate Center Drive, Morrow, GA 30260.

×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
    • Abstract
    • Smallpox Vaccine (Vaccinia Virus)
    • Normal Vaccination Response
    • Clinical Features of Major Adverse Events after Vaccination
    • Treatment of Adverse Events after Smallpox Vaccination
    • Rates of Adverse Events after Smallpox Vaccination
    • Adverse Events after the New Smallpox Vaccination
    • Estimated Number of Deaths from Widespread Vaccination in 21st-Century United States
    • Dynamics of Smallpox Transmission
    • Risks and Benefits of Various Vaccination Strategies
      1. References
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link

Abstract

The United States stopped vaccinating against smallpox in 1972 because the risks were judged to outweigh the benefits. The possibility of a terrorist attack using smallpox has led to renewed interest in a vaccination program. Smallpox vaccination carries considerable risks, which may be of greater concern today than in the late 1960s because of the increased prevalence of immunosuppression and atopy in the population. This paper reviews the clinical presentations of major adverse events after vaccination and the rates of occurrence of these events observed in the 1960s. The normal dynamics of the spread of smallpox is slow, and usually only persons who have had close personal contact with an overtly ill patient are affected. There are several preattack vaccination policy options, but immunization of medical workers, especially those who might have close contact with infected patients, is sufficient in the absence of a known threat of a bioterrorist attack or the identification of a smallpox-infected person.

The United States stopped routine vaccination against smallpox in 1972. Studies performed in the 1960s documented that the risk for serious complications from smallpox vaccination was greater than the estimated risk for reintroduction of smallpox itself (1). Studies of European outbreaks after reintroduction of smallpox showed that spread of the disease was usually minimal once public health containment efforts were instituted (2, 3). In the 1960s and 1970s, inadvertent importation from endemic nations posed a risk for smallpox. Concerns about bioterrorism now raise the possibility that the risk from intentional release may justify resumption of vaccination (4-7).
A spectrum of vaccination strategies should be considered before an initial case has occurred or a specific threat of a bioterrorist attack has been received. We could resume routine vaccination of the entire population. We could vaccinate first responders who might care for or investigate persons suspected of having smallpox and their contacts. We could allow individual citizens to make their own choices concerning immunization after informing the public about the risks of vaccination and the potential threat for smallpox. We could continue to pursue the current policy that considers the risk for smallpox to be too low to justify the risks of vaccination. The Advisory Committee on Immunization Practices initially suggested vaccinating a very limited number of persons who might be involved in the early investigation of possible smallpox cases (8) but is now suggesting a more widespread program for first responders (9).
We describe the smallpox vaccine; review risks from vaccination, as observed in the 1960s; and estimate the actual number of deaths from vaccination that might occur after widespread vaccination today. We also comment on the risk for spread of smallpox from a bioterrorism attack and briefly discuss preattack vaccination policy options.

Smallpox Vaccine (Vaccinia Virus)

Vaccinia is a live-virus vaccine. In the United States, vaccine is made by using the New York City Board of Health (NYCBOH) strain of vaccinia, which was the safest of the strains in common use in the 20th century (3). The virus was grown on the skin of cows and then purified in production laboratories to produce the final product. Wet, glycerinated lymph was often used in smallpox vaccine in the 1960s and earlier, but after about 1970, most smallpox vaccine was lyophilized to preserve its stability when exposed to heat. Good vaccine has a titer of about 10 8 pock-forming units per mL (3). Successful vaccination (reported as take rates) will be achieved in almost 100% of previously unvaccinated persons and will be high in previously vaccinated persons. Vaccine of this titer that is diluted 1:10 successfully immunizes most vaccinees when administered with a bifurcated needle (10). New vaccine is currently being made by using the same NYCBOH strain on cell cultures (Vero cells and human MRC5 cells). When this vaccine is licensed in late 2003 and added to the approximately 70 million doses of currently available vaccine, the vaccine supply will be more than adequate for the entire U.S. population.

Normal Vaccination Response

Successful vaccination requires replication of virus at the vaccination site. After vaccinia is successfully introduced into the Malphigian layer of the skin, it multiplies. In fully susceptible persons (primary vaccinees), very little is visible at the site for 3 or 4 days. Then, a papule forms, which matures into a vesicle, and then a pustule, over the next 4 or 5 days. The lesion is largest about 8 days after vaccination. The cardinal signs of inflammation are present from about day 5 to day 10 after vaccination, and mild fever with or without lymphadenopathy is common. Viremia is rare with the NYCBOH strain (11, 12). Neutralizing antibodies and evidence of cellular immunity can be detected starting from about day 8 or 9 after vaccination (3). The lesion then begins to involute and a scab forms, which comes off about 2 weeks after vaccination, leaving a small scar. Virus can be recovered from the vaccination site and scab during most of this process.
Successful revaccination results in a lesion similar to that of primary vaccination, but the clinical course of the response is milder and accelerated to a varying degree, depending on the amount of residual immunity. If the virus replicates, a central lesion that is surrounded by some degree of inflammation and induration can be seen 6 to 8 days after vaccination; this lesion may be a pustule, ulcer, or scab. Revaccination of a highly immune individual may result in a lesion similar to a positive tuberculin test, with some itching and redness at the site. This lesion resolves fully by about day 3, and nothing is evident 6 to 8 days after vaccination. This type of lesion is the result of 1) high immunity and a good vaccination or 2) modest immunity and poor-quality vaccine or poor vaccination technique. It was once called the reaction of immunity but is now called an equivocal response (3). Persons with this response, especially those at serious risk for developing smallpox, should be revaccinated with known high-quality vaccine using vigorous technique.
Primary vaccination is a viral infection in a nonimmune host and causes rare but significant complications. Most of these occur between 5 and 15 days after vaccination, when the vaccinia virus is actively replicating and the immune system is vigorously responding. Most adverse events occur after primary vaccination because previous immunization with vaccinia protects very well against its own adverse effects. The adverse events associated with revaccination generally occur in older patients who have not been vaccinated for decades or patients who have developed severe cellular immune deficiency with or without a humoral deficit.

Clinical Features of Major Adverse Events after Vaccination

There are three types of rare but potentially fatal adverse events and three common but clinically mild ones. These will be described in the following sections. Photographs of major adverse events (those not associated with the central nervous system) are available at www.bt.cdc.gov/training/smallpoxvaccine/reactions.

Postvaccinial Central Nervous System Disease

Postvaccinial central nervous system (CNS) disease (encephalitis, encephalomyelitis, and encephalopathy) is rare but potentially fatal. Disease usually develops 5 to 15 days after primary vaccination. About 25% of patients die, 25% have residual CNS sequelae, and the remainder recover. The clinical course is similar to that of other postinfectious encephalitides. Patients may present with coma, obtundation, seizures, focal or lateralizing signs, or virtually any CNS symptom. Very few patients have live virus in the brain or cerebrospinal fluid, suggesting that most of these adverse events are immune mediated. The disease is not progressive; the clinical course is complete within about 2 weeks. DeVries distinguished between encephalopathy (edema of the brain without inflammation), which occurred predominantly in children younger than 2 years old, and encephalitis (characterized by perivascular cuffing and pathologic signs similar to those of other postinfectious encephalitides) (13). No known factors increase risk enough to serve as contraindications to vaccination, although the increased rate of postvaccinial encephalitis in infants younger than 1 year of age led to delay of vaccination until the second year of life in the mid-1960s. Supportive care is essentially the only therapy.

Progressive Vaccinia

Progressive vaccinia, also called vaccinia necrosum or vaccinia gangrenosum, can occur after vaccination in patients with severely compromised immune systems. The cardinal signs of inflammation are not seen as part of the vaccination response, and, because of continued viral replication, the lesion continues to enlarge and metastasize beyond the usual time of scab formation (14). Disease may not be diagnosed in these patients until 2 or more weeks after inoculation. Most patients who developed progressive vaccinia in the 1960s had leukemia or agammaglobulinemia. In today's environment, we must focus our concern on patients who have severe HIV infection and AIDS, transplantation-related immunosuppression, malignant disorders being treated with chemotherapy, and other iatrogenic immunosuppressive disorders. Vigorous therapy with vaccinia immune globulin (VIG), modern immunoreconstruction, and perhaps modern antiviral agents (such as cidofovir or its analogues) may reduce mortality rates (15).

Eczema Vaccinatum

Eczema vaccinatum is characterized by widespread vaccinial lesions over the body of patients with eczema (true atopic dermatitis) or a history of atopic dermatitis. Patients lose fluid and electrolytes through the skin, similar to patients with severe burns, with the attendant risks for dehydration and organ failure. Modern approaches to burn therapy may help decrease the mortality rate. In the 1960s, death from eczema vaccinatum occurred more frequently in patients who were not vaccinated but who were close contacts of recently vaccinated family members (16). This was probably because of the recognition that patients with obvious eczema should not be immunized. Vigorous therapy with VIG and good supportive care reduced the fatality rate from about 10% in the era before VIG was used to only about 1% (12, 17, 18). Eczema vaccinatum rarely occurred in patients with atopic dermatitis who had been previously vaccinated and who had robust immunity; therefore, after these patients are vaccinated, frequent revaccination is considered appropriate.

Accidental Implantations, Erythematous or Urticarial Rashes, and Generalized Vaccinia

More common but of less concern are accidental implantations, erythematous or urticarial rashes, and generalized vaccinia. Accidental implantation occurs when a patient touches the vaccination site and then touches an eye, the anus or genitals, or areas of abraded skin (such as the lesions of poison ivy). The result is a vaccinia lesion distant from the intended vaccination site. When vaccinia infects the eye, an ophthalmologist should be consulted to examine for keratitis. About 6% of patients with vaccinia in the eye develop vaccinial keratitis (19). Vaccinia immune globulin is contraindicated in these patients; experimental data in rabbits showed that antigenantibody precipitates occur in the cornea and cause scaring (20).
Widespread blotchy macular rashes, often with dramatic erythema or urticaria, are very common, especially in toddlers. Affected patients are generally not ill and do very well without therapy. Rarely, a true StevensJohnson syndrome rash occurs, which requires more vigorous medical intervention. There is a blurry spectrum of these rashes, many of which are labeled generalized vaccinia. This term implies that the vaccinia virus has become blood-borne and has spread throughout the body. With erythematous or urticarial rashes, virus does not replicate in peripheral lesions; true generalized spread of the virus with virus-containing peripheral pustules is uncommon.

Fetal Vaccinia

Pregnancy is a relative contraindication to vaccination because of the accepted practice of avoiding live virus vaccines during pregnancy. Limited data do not show that vaccinia is teratogenic or that it leads to increased fetal wastage. A very small number of cases of fetal vaccinia (usually presenting with scars or pock marks or both) have been reported, but this is exceedingly rare. Pregnant women exposed to smallpox should be vaccinated. In pregnant women, smallpox has been associated with very high rates of mortality (almost 90% in some series) and fetal wastage (almost 100%).

Treatment of Adverse Events after Smallpox Vaccination

Treatment of adverse events after vaccination is not standardized (21). Clinical trials have not been conducted because the frequency of serious problems was low. Vaccinia immune globulin was introduced by Kempe (12) in 1959 and became a standard therapy for progressive vaccinia and eczema vaccinatum. It clearly contributed to the decline in mortality from these conditions. Vaccinia immune globulin is made from the blood of highly immune, recently vaccinated donors and is administered by intramuscular injection in large doses. Currently, supplies are limited and could be exhausted by treatment of several patients with progressive vaccinia or eczema vaccinatum (22). Efforts are under way to increase the supply of VIG (22, 23), but its scarcity should be considered when vaccination policy is being formulated.
In the 1960s, Marboran (N-methylisatin -thiosemicarbazone), an early antiviral agent, was used to treat patients with progressive vaccinia and was believed to contribute to the decline in mortality rates. Because Marboran is currently unavailable, lacks FDA approval, and is not supported by good clinical trials, clinicians today would probably use cidofovir (which has in vitro activity against vaccinia) or one of its more bioavailable and perhaps less toxic analogues (15, 23). At present, cidofovir is recommended only for the treatment of cytomegalovirus retinitis and would be used to treat severe adverse events after vaccination under an Investigational New Drug protocol.

Rates of Adverse Events after Smallpox Vaccination

Table 1 presents the frequency of adverse events in primary vaccinees who were vaccinated with the NYCBOH strain of vaccinia. These rates are based on studies conducted in 1968. The rates for death, postvaccinial encephalitis, and progressive vaccinia are taken from national surveillance data (18). The rates for the common but less important adverse events are from studies in 10 small states that actively searched for cases (24). The high rate of erythematous rashes in toddlers comes from a cohort study in a Johns Hopkins University comprehensive care clinic (25). Frey and colleagues (10) found a similar high rate of rashes in 680 adult primary vaccinees.

Table 1. Frequency of Adverse Events in 1968 after Primary Smallpox Vaccination with New York Board of Health Strain Vaccinia, by Age and Type of Adverse Event

Table 1. Frequency of Adverse Events in 1968 after Primary Smallpox Vaccination with New York Board of Health Strain Vaccinia, by Age and Type of Adverse Event
The overall death rates presented in Table 1 do not fully reflect the risks associated with vaccination because the deaths from eczema vaccinatum in contacts of vaccinated patients (rather than those who were directly vaccinated) cannot be assigned to a denominator of either primary or revaccinees. During the 1960s, when 5 to 6 million primary vaccinations were performed each year in the United States, one or two contacts each year died of eczema vaccinatum (16). Transmission of vaccinia is rare and requires close contact. Transmission from health care workers to patients is very rare but has been documented (26).
Table 2 presents the analogous data for revaccinees. The rates are considerably lower because vaccinia is such a good vaccine against itself. Most adverse events occurred in patients vaccinated many years previously, in whom immunity had presumably waned considerably. The rate for progressive vaccinia does not differ greatly from the rate in primary vaccinees because acquisition of an immune deficit negates most of the benefit from previous vaccination.

Table 2. Frequency of Adverse Events in 1968 after Smallpox Revaccination with New York Board of Health Strain Vaccinia, by Age and Type of Adverse Event

Table 2. Frequency of Adverse Events in 1968 after Smallpox Revaccination with New York Board of Health Strain Vaccinia, by Age and Type of Adverse Event

Adverse Events after the New Smallpox Vaccination

Growing vaccinia on live cows presents problems with bacterial contamination. Vaccinia grows readily on many tissue culture cell lines, and the vigorous work on recombinant vaccinia strains in the past two decades has contributed to the technology of growing and harvesting the virus (27). The new vaccine that is becoming available consists of seed virus of the NYCBOH strain, grown on either Vero cells or the MRC5 cell line (23). There is no way to predict whether this change in substrate will alter any of the characteristics of the virus. Presumably, a small number of passages on human cells will have little effect, but it is premature to guarantee that the rates of adverse effects found associated with NYCBOH calf vaccine in 1968 will be identical to those found now.
Existing further attenuated strains and inactivated vaccines do not reliably produce cellular and humoral immunity. They have not been shown to protect against smallpox, and some have interfered with development of antibody after challenge with full-strength vaccinia (27-30).

Estimated Number of Deaths from Widespread Vaccination in 21st-Century United States

About 120 million (42%) of the 282 million persons in the current U.S. population were born after 1972 and have never been vaccinated. Virtually all of the other 162 million have not been vaccinated for at least 30 years. Serologic and epidemiologic data suggest that some residual immunity persists for as long as 30 years (31-33). A considerable, if unknown, proportion of this older population may have so little residual immunity that they react to the vaccine like primary vaccinees, with the risks associated with a naive state of immunity.
Table 3 presents a conservative estimate of the number of deaths that could be expected from widespread attempts to immunize the entire U.S. population. We should expect a minimum of 125 deaths. This assumes resumption of the late 1960's policy of not vaccinating infants younger than 1 year of age and a vigorous and successful effort to screen out and protect immunosuppressed patients from contact with vaccinees. This estimate also does not consider patients dying of eczema vaccinatum acquired by contact, despite the increased prevalence of serious atopic dermatitis today as compared with the 1960s (34).

Table 3. Conservative Estimate of Deaths from Smallpox Vaccination after Implementation of a Policy of Indiscriminate Widespread Vaccination

Table 3. Conservative Estimate of Deaths from Smallpox Vaccination after Implementation of a Policy of Indiscriminate Widespread Vaccination
The number of deaths after smallpox vaccination in the 21st century might be considerably higher than the number in the late 1960s. The rate of progressive vaccinia in adults and the resultant vaccination-related mortality would be higher because of the greatly increased prevalence of severe immunodeficiencyacquired or induced by therapeutic interventionsin our society today. Transient but severe immunosuppression as a result of the use of high-dose steroid therapy in patients with asthma or autoimmune syndromes may also predispose patients to serious adverse consequences after vaccination. We estimate that about 100 000 patients are immunosuppressed after transplantation, 100 000 patients with HIV have low T-cell counts, and about 120 000 patients with various malignant disorders are immunosuppressed after receiving chemotherapy or radiation therapy. Because true atopic dermatitis is more prevalent today than in the 1960s, deaths from eczema vaccinatum might increase (33). If panic resulting from a terrorist attack led to widespread vaccination, death rates could be much higher than in 1968. Two methods can reduce deaths and serious adverse events from vaccination. First is prudent screening of potential vaccinees. Second is handling outbreaks by isolating patients and vaccinating their contacts, the surveillance and containment method used to eradicate smallpox.

Dynamics of Smallpox Transmission

Smallpox does not spread rapidly under natural conditions. Well-conducted studies of variola major in the Asian subcontinent in the late 1960s showed that each case of smallpox gave rise to about three new cases during the seasonal upswing of the disease and less than one case during the seasonal downswing (35-39). In European importation outbreaks after World War II, the spread was often more limited, unless nosocomial spread occurred in hospitals (2). The largest European outbreak, which occurred in Yugoslavia in 1972, included two hyper spreaders. One patient with hemorrhagic smallpox had been misdiagnosed as having a severe allergic reaction to penicillin; many hospital staff saw this patient. Smallpox spread from this one patient to 38 people, all but 1 of whom were hospital contacts. Another person with smallpox spread the disease to at least 16 and perhaps 23 contacts. Ultimately, there were cases of smallpox in Belgrade, 5 towns outside Belgrade and Kosovo province, and 18 villages in Kosovo. Despite this impressive spread, the outbreak was rapidly terminated once it was recognized (40). Analysis of epidemics in the prevaccination era supports the leisurely spread of the disease (41).
Careful mathematical modeling of the natural spread of smallpox shows that a reasonable mix of judicious vaccination of close contacts and effective isolation of patients can readily stop outbreaks within two infective generations (about 4 weeks) after recognition of the initial cases (42, 43).
The draft plan from the CDC for handling a smallpox bioterrorism event concludes that rigorous patient isolation, with vaccination of contacts and their contacts, would be preferable to mass vaccination in the event of a terrorist attack (44). Smallpox is spread only from sick persons, many of whom would be prostrate and immobile. Spread from patients does not occur during the incubation period. Smallpox usually occurs in persons who have had close, prolonged contact (not casual or distant contact) with a sick person. Vaccination in the first two or three days after contact generally aborts or greatly alleviates the disease. This method of containment, which led to the ultimate eradication of smallpox, requires relatively few vaccinations for the contacts of each actual case.
Because smallpox is spread through respiratory secretions, isolation and simple properly fitting N95 respirator masks (45) prevent disease propagation. Patients should wear these masks and should be kept in negative-pressure hospital rooms. True small-droplet aerosol spread, although rare, has been documented; a single patient spread smallpox to 17 people in a hospital in Germany (46).

Risks and Benefits of Various Vaccination Strategies

Any policy that increases vaccinations will lead to an increase in morbidity and mortality associated with vaccinia. We could resume routine vaccination of the entire U.S. population to reduce the chance of a major outbreak after a terrorist attack. Since no current creditable threat exists and such a policy might cost between 125 and 500 lives, this seems unwise.
We could vaccinate first responders who might be involved in caring for or investigating patients with suspected smallpox and their contacts. This strategy might protect those most likely to initially bear the risk for acquiring smallpox. A major problem might be that some of these persons have frequent daily contact with patients with HIV infection or patients who are immunosuppressed as a result of cancer therapy or transplantation. The turnover rate of such personnel is considerable, and such a policy might have to be continuous until intelligence discounts any possible risk for a smallpox attack. At present, there is no way to predict how long such a policy might have to continue.
We might allow citizens to make individual choices about obtaining vaccination after they have been given information about the risks associated with vaccination and potential threat of smallpox (5, 6). Public health authorities would thus cede decisions on a policy with considerable technical ramifications to persons with widely varying abilities to comprehend and weigh the risks and benefits. The media and the medical profession would have to communicate an accurate portrayal of the data and options. In the absence of a known threat of smallpox exposure, this option would be dangerous to many potential vaccinees, their contacts, and the public health initiative. It would subject the population to a known risk for severe adverse events. The publicity about such complications might subsequently keep some persons from accepting vaccination if the need actually arises.
We could continue to pursue the current policy of avoiding mass vaccination while vaccinating small numbers of first responders and personnel who might be involved in the investigation and control of possible smallpox outbreaks. This should be and is being accompanied by an effort to build vaccine supplies, institutionalize vaccine production capacity, develop and expand laboratory expertise, and train public health authorities and first-response clinicians. While these options should be revisited periodically as new information comes to light, at present it seems prudent to continue the present policy and to initiate only modest increases in vaccination of first responders.

References

  1. Lane
    JM
    ,  
    Millar
    JD
    .  
    Routine childhood vaccination against smallpox reconsidered
    N Engl J Med
    1969
    281
    1220
    4
     PubMed
    CrossRef
     PubMed
  2. Mack
    TM
    .  
    Smallpox in Europe, 1950-1971
    J Infect Dis
    1972
    125
    161
    9
     PubMed
    CrossRef
     PubMed
  3. Fenner
    F
    ,  
    Henderson
    DA
    ,  
    Arita
    I
    ,  
    Jezek
    Z
    ,  
    Ladnyi
    ID
    .  
    Smallpox and Its Eradication
    Geneva, Switzerland
    World Health Organization
    1988
  4. Henderson
    DA
    ,  
    Inglesby
    TV
    ,  
    Bartlett
    JG
    ,  
    Ascher
    MS
    ,  
    Eitzen
    E
    ,  
    Jahrling
    PB
    ,  
    et al.
    .  
    Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense
    JAMA
    1999
    281
    2127
    37
     PubMed
    CrossRef
     PubMed
  5. Bicknell
    WJ
    .  
    The case for voluntary smallpox vaccination
    N Engl J Med
    2002
    346
    1323
    5
     PubMed
    CrossRef
     PubMed
  6. de Rugy V, Pena CV. Responding to the Threat of Smallpox Bioterrorism: An Ounce of Prevention is Best Approach. Cato Policy Analysis No. 434. 18 April 2002.
  7. Fauci
    AS
    .  
    Smallpox vaccination policythe need for dialogue [Editorial]
    N Engl J Med
    2002
    346
    1319
    20
     PubMed
     PubMed
  8. Vaccinia (Smallpox) Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001
    MMWR Morb Mortal Wkly Rep
    2001
    50
    RR-10
    1
    22
     PubMed
  9. Stevenson RW, Stolberg SG. Bush lays out plan on smallpox shots; military is first. New York Times. December 2002; A1.
  10. Frey
    SE
    ,  
    Couch
    RB
    ,  
    Tacket
    CO
    ,  
    Treanor
    JJ
    ,  
    Wolff
    M
    ,  
    Newman
    FK
    ,  
    et al.
    .  
    Clinical responses to undiluted and diluted smallpox vaccine
    N Engl J Med
    2002
    346
    1265
    74
     PubMed
    CrossRef
     PubMed
  11. Blattner
    RJ
    ,  
    Norman
    JO
    ,  
    Heys
    FM
    ,  
    Aksu
    I
    .  
    Antibody response to cutaneous inoculation with vaccinia virus: viremia and viruria in vaccinated children
    J Pediatr
    1964
    64
    839
    52
    CrossRef
     PubMed
  12. Kempe
    CH
    .  
    Studies on smallpox and complications of smallpox vaccination
    Pediatrics
    1960
    26
    176
    89
     PubMed
  13. DeVries
    E
    .  
    Postvaccinial Perivenous Encephalitis
    Amsterdam
    Elsevier
    1959
  14. Fulginiti VA, Kempe CH, Hathaway WE, Pearlman DS, Sieber OF, Eller JJ, et al. Progressive vaccinia in immunologically deficient individuals. New York: The National Foundation-March of Dimes, Birth Defects, Original Article Series, Immunologic Deficiency Diseases in Man. 1968; 4:129-45.
  15. Bradbury
    J
    .  
    Orally available cidofovir derivative active against smallpox
    Lancet
    2002
    359
    1041
     PubMed
    CrossRef
     PubMed
  16. Lane
    JM
    ,  
    Ruben
    FL
    ,  
    Abrutyn
    E
    ,  
    Millar
    JD
    .  
    Deaths attributable to smallpox vaccination, 1959 to 1966, and 1968
    JAMA
    1970
    212
    441
    4
     PubMed
    CrossRef
     PubMed
  17. Copeman
    PM
    ,  
    Wallace
    HJ
    .  
    Eczema vaccinatum
    BMJ
    1964
    2
    906
    8
    CrossRef
     PubMed
  18. Lane
    JM
    ,  
    Ruben
    FL
    ,  
    Neff
    JM
    ,  
    Millar
    JD
    .  
    Complications of smallpox vaccination, 1968
    N Engl J Med
    1969
    281
    1201
    8
     PubMed
    CrossRef
     PubMed
  19. Ruben
    FL
    ,  
    Lane
    JM
    .  
    Ocular vaccinia. An epidemiologic analysis of 348 cases
    Arch Ophthalmol
    1970
    84
    45
    8
     PubMed
    CrossRef
     PubMed
  20. Fulginiti
    VA
    ,  
    Winograd
    LA
    ,  
    Jackson
    M
    ,  
    Ellis
    P
    .  
    Therapy of experimental vaccinal keratitis. Effect of idoxuridine and VIG
    Arch Ophthalmol
    1965
    74
    539
    44
     PubMed
    CrossRef
     PubMed
  21. Goldstein
    JA
    ,  
    Neff
    JM
    ,  
    Lane
    JM
    ,  
    Koplan
    JP
    .  
    Smallpox vaccination reactions, prophylaxis, and therapy of complications
    Pediatrics
    1975
    55
    342
    7
     PubMed
     PubMed
  22. Rosenthal
    SR
    ,  
    Merchlinsky
    M
    ,  
    Kleppinger
    C
    ,  
    Goldenthal
    KL
    .  
    Developing new smallpox vaccines
    Emerg Infect Dis
    2001
    7
    920
    6
     PubMed
    CrossRef
     PubMed
  23. LeDuc
    JW
    ,  
    Damon
    I
    ,  
    Meegan
    JM
    ,  
    Relman
    DA
    ,  
    Huggins
    J
    ,  
    Jahrling
    PB
    .  
    Smallpox research activities: U.S. interagency collaboration, 2001
    Emerg Infect Dis
    2002
    8
    743
    5
     PubMed
    CrossRef
     PubMed
  24. Lane
    JM
    ,  
    Ruben
    FL
    ,  
    Neff
    JM
    ,  
    Millar
    JD
    .  
    Complications of smallpox vaccination, 1968: results of ten statewide surveys
    J Infect Dis
    1970
    122
    303
    9
     PubMed
    CrossRef
     PubMed
  25. Neff
    JM
    ,  
    Lane
    JM
    ,  
    Fulginiti
    VA
    ,  
    Henderson
    DA
    .  
    Contact vacciniatransmission of vaccinia from smallpox vaccination
    JAMA
    2002
    288
    1901
    5
     PubMed
    CrossRef
     PubMed
  26. Neff
    JM
    ,  
    Drachman
    RH
    .  
    Complications of smallpox vaccination, 1968 surveillance in a Comprehensive Care Clinic
    Pediatrics
    1972
    50
    481
    3
     PubMed
     PubMed
  27. Henderson
    DA
    ,  
    Moss
    B
    .  
    Vaccines. 3rd ed
    Philadelphia
    WB Saunders
    1999
  28. Stittelaar
    KJ
    ,  
    Kuiken
    T
    ,  
    de Swart
    RL
    ,  
    van Amerongen
    G
    ,  
    Vos
    HW
    ,  
    Niesters
    HG
    ,  
    et al.
    .  
    Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques
    Vaccine
    2001
    19
    3700
    9
     PubMed
    CrossRef
     PubMed
  29. Tartaglia
    J
    ,  
    Perkus
    ME
    ,  
    Taylor
    J
    ,  
    Norton
    EK
    ,  
    Audonnet
    JC
    ,  
    Cox
    WI
    ,  
    et al.
    .  
    NYVAC: a highly attenuated strain of vaccinia virus
    Virology
    1992
    188
    217
    32
     PubMed
    CrossRef
     PubMed
  30. Enserink
    M
    .  
    Bioterrorism. in search of a kinder, gentler vaccine
    Science
    2002
    296
    1594
     PubMed
    CrossRef
     PubMed
  31. Demkowicz
    WE
    Jr
    ,  
    Littaua
    RA
    ,  
    Wang
    J
    ,  
    Ennis
    FA
    .  
    Human cytotoxic T-cell memory: long-lived responses to vaccinia virus
    J Virol
    1996
    70
    2627
    31
     PubMed
     PubMed
  32. Cohen
    J
    .  
    Bioterrorism. Smallpox vaccinations: how much protection remains?
    Science
    2001
    294
    985
     PubMed
    CrossRef
     PubMed
  33. el-Ad
    B
    ,  
    Roth
    Y
    ,  
    Winder
    A
    ,  
    Tochner
    Z
    ,  
    Lublin-Tennenbaum
    T
    ,  
    Katz
    E
    ,  
    et al.
    .  
    The persistence of neutralizing antibodies after revaccination against smallpox
    J Infect Dis
    1990
    161
    446
    8
     PubMed
    CrossRef
     PubMed
  34. Raimer
    SS
    .  
    Managing pediatric atopic dermatitis
    Clin Pediatr (Phila)
    2000
    39
    1
    14
     PubMed
    CrossRef
     PubMed
  35. Thomas
    DB
    ,  
    Arita
    I
    ,  
    McCormack
    WM
    ,  
    Khan
    MM
    ,  
    Islam
    S
    ,  
    Mack
    TM
    .  
    Endemic smallpox in rural East Pakistan. II. Intervillage transmission and infectiousness
    Am J Epidemiol
    1971
    93
    373
    83
     PubMed
    CrossRef
     PubMed
  36. Mack
    TM
    ,  
    Thomas
    DB
    ,  
    Muzaffar Khan
    M
    .  
    Epidemiology of smallpox in West Pakistan. II. Determinants of intravillage spread other than acquired immunity
    Am J Epidemiol
    1972
    95
    169
    77
     PubMed
    CrossRef
     PubMed
  37. Rao
    AR
    ,  
    Jacob
    ES
    ,  
    Kamalakshi
    S
    ,  
    Appaswamy
    S
    .  
    Bradbury
    Epidemiological studies in smallpox. A study of intrafamilial transmission in a series of 254 infected families
    Indian J Med Res
    1968
    56
    1826
    54
     PubMed
     PubMed
  38. Sommer
    A
    ,  
    Foster
    SO
    .  
    The 1972 smallpox outbreak in Khulna Municipality, Bangladesh. I. Methodology and epidemiologic findings
    Am J Epidemiol
    1974
    99
    291
    302
     PubMed
    CrossRef
     PubMed
  39. Mukherjee
    MK
    ,  
    Sarkar
    JK
    ,  
    Mitra
    AC
    .  
    Pattern of intrafamilial transmission of smallpox in Calcutta, India
    Bull World Health Organ
    1974
    51
    219
    25
     PubMed
     PubMed
  40. CDC EPI-SEP-72-91-2. Smallpox in Yugoslavia. Atlanta: Centers for Disease Control and Prevention; 22 September 1972.
  41. Gani
    R
    ,  
    Leach
    S
    .  
    Transmission potential of smallpox in contemporary populations
    Nature
    2001
    414
    748
    51
     PubMed
    CrossRef
     PubMed
  42. Meltzer
    MI
    ,  
    Damon
    I
    ,  
    LeDuc
    JW
    ,  
    Millar
    JD
    .  
    Modeling potential responses to smallpox as a bioterrorist weapon
    Emerg Infect Dis
    2001
    7
    959
    69
     PubMed
    CrossRef
     PubMed
  43. Enserink
    M
    .  
    Bioterrorism. How devastating would a smallpox attack really be?
    Science
    2002
    296
    1592
    5
     PubMed
    CrossRef
     PubMed
  44. CDC Smallpox Response Plan and Guidelines (version 3.0), November 2002. Accessed at www.bt.cdc.gov/agent/smallpox/response-plan/index.asp on 13 January 2003.
  45. Harber
    P
    ,  
    Barnhart
    S
    ,  
    Boehlecke
    BA
    ,  
    Beckett
    WS
    ,  
    Gerrity
    T
    ,  
    McDiarmid
    MA
    ,  
    et al.
    .  
    Respiratory protection guidelines. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, March 1996
    Am J Respir Crit Care Med
    1996
    154
    1153
    65
     PubMed
    CrossRef
     PubMed
  46. Wehrle
    PF
    ,  
    Posch
    J
    ,  
    Richter
    KH
    ,  
    Henderson
    DA
    .  
    An airborne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe
    Bull World Health Organ
    1970
    43
    669
    79
     PubMed
     PubMed

Table 1. Frequency of Adverse Events in 1968 after Primary Smallpox Vaccination with New York Board of Health Strain Vaccinia, by Age and Type of Adverse Event

Table 1. Frequency of Adverse Events in 1968 after Primary Smallpox Vaccination with New York Board of Health Strain Vaccinia, by Age and Type of Adverse Event

Table 2. Frequency of Adverse Events in 1968 after Smallpox Revaccination with New York Board of Health Strain Vaccinia, by Age and Type of Adverse Event

Table 2. Frequency of Adverse Events in 1968 after Smallpox Revaccination with New York Board of Health Strain Vaccinia, by Age and Type of Adverse Event

Table 3. Conservative Estimate of Deaths from Smallpox Vaccination after Implementation of a Policy of Indiscriminate Widespread Vaccination

Table 3. Conservative Estimate of Deaths from Smallpox Vaccination after Implementation of a Policy of Indiscriminate Widespread Vaccination

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

Lane JM, Goldstein J. Evaluation of 21st-Century Risks of Smallpox Vaccination and Policy Options. Ann Intern Med. 2003;138:488–493. doi: https://doi.org/10.7326/0003-4819-138-6-200303180-00014

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2019

×
Permissions

Published: Ann Intern Med. 2003;138(6):488-493.

DOI: 10.7326/0003-4819-138-6-200303180-00014

©
2003 American College of Physicians
46 Citations

See Also

Smallpox Vaccination Risks and Public Policy
Smallpox Vaccination Risks and Public Policy
View MoreView Less

Related Articles

The Importance of Reporting Biases in Patient Care: Can We Trust the Evidence From Either Individual Studies or Systematic Reviews?
Annals of Internal Medicine; 169 (6): 413-414
Evaluating Vaccination Strategies for Zika Virus in the Americas
Annals of Internal Medicine; 168 (9): 621-630
Sodium bicarb vs sodium chloride, and acetylcysteine vs placebo, did not differ for adverse events after angiography
Annals of Internal Medicine; 168 (4): JC22
Low Prevalence of Hepatitis B Vaccination Among Patients Receiving Medical Care for HIV Infection in the United States, 2009 to 2012
Annals of Internal Medicine; 168 (4): 245-254
View MoreView Less

Journal Club

Sodium bicarb vs sodium chloride, and acetylcysteine vs placebo, did not differ for adverse events after angiography
Annals of Internal Medicine; 168 (4): JC22
In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin + clopidogrel reduced adverse events
Annals of Internal Medicine; 167 (6): JC28
Review: α-blockers increase passage of ureteric stones without increasing serious adverse events
Annals of Internal Medicine; 166 (6): JC33
Review: Pregabalin reduces fibromyalgia pain but increases adverse events
Annals of Internal Medicine; 166 (2): JC2
View MoreView Less

Related Topics

Bioterrorism Infectious Agents
Infectious Disease
Prevention/Screening
Vaccines/Immunization

Bioterrorism Infectious Agents, Infectious Disease, Prevention/Screening, Vaccines/Immunization.

PubMed Articles

ANTIPNEUMOCOCCAL SEROPROTECTION YEARS AFTER VACCINATION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS.
Clin Infect Dis 2019.
Mucosal and systemic immune responses to Aujeszky's disease virus (ADV) in early vaccinated piglets.
Comp Immunol Microbiol Infect Dis 2019;
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×